Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors' Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology.
Evidence-based guidelines are presented on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. They include details of therapeutic products available in the UK and they update and replace previous United Kingdom Haemophilia Centre Doctors' Organisation guidelines.
Keeling
D
D
Oxford Haemophilia and Thrombosis Centre, Churchill Hospital, Oxford.
Tait
C
C
Makris
M
M
D001323:Autoantibodies / Q000096:biosynthesis; D025861:Blood Coagulation Disorders, Inherited / Q000188:drug therapy*; D001779:Blood Coagulation Factors / Q000627:therapeutic use; D017848:Blood-Borne Pathogens; D003029:Coagulants / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D019317:Evidence-Based Medicine / Q000379:methods; D006467:Hemophilia A / Q000188:drug therapy; D002836:Hemophilia B / Q000188:drug therapy; D006801:Humans; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use; D013927:Thrombosis / Q000139:chemically induced; D038301:Virus Inactivation
D001323:Autoantibodies; D001779:Blood Coagulation Factors; D003029:Coagulants; D011994:Recombinant Proteins